![]() These statements speak only as of today’s date and we undertake no duty to update or revise them. A description of these risks can be found in our most recent 10-Q on file with the SEC. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. The press release reporting our financial results in addition to the presentation for today’s webcast can be accessed by going to the Investor Relations section of the corporate website at Joining me in the room today with prepared remarks are Bob Hugin, our Chairman and Chief Executive Officer Jacquie Fouse, our Chief Financial Officer Mark Alles, who is Global Head of our Hematology and Oncology franchise and the Global Head of our Inflammation and Immunology franchise, Scott Smith.Īs a reminder, during today’s call we will be making forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. Thanks, Nicole, and welcome everyone to our second quarter earnings conference call. I would now like to turn the conference over to Patrick Flanigan, Vice President, Investor Relations at Celgene. I would like to remind you that this call is being recorded. All participants will be in a listen-only mode until the question and answer session at the end of the conference. ![]() Good morning and welcome to the Celgene Second Quarter 2014 Earnings conference call. Patrick Flanigan – Vice President, Investor Relations Scott Smith – Global Head, Inflammation and Immunology Mark Alles – Global Head, Hematology and Oncology Jacqualyn Fouse – Executive Vice President, Chief Financial Officer Robert Hugin – Chairman, Chief Executive Officer Celgene Corporation ( NASDAQ: CELG) Q2 2014 Earnings Conference Call J9:00 AM ET
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |